期刊论文详细信息
EJNMMI Research | |
Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review | |
Patrick Lugenbiel1  Eberhard Scholz2  Frederik L. Giesel3  Uwe Haberkorn4  Sebastian Adeberg5  Jürgen Debus5  Daniel R. Zwahlen6  Paul Windisch6  | |
[1]Department of Cardiology, Heidelberg University Hospital, Heidelberg, Germany | |
[2]Heidelberg Center for Heart Rhythm Disorders (HCR), Heidelberg University Hospital, Heidelberg, Germany | |
[3]Department of Cardiology, Heidelberg University Hospital, Heidelberg, Germany | |
[4]Heidelberg Center for Heart Rhythm Disorders (HCR), Heidelberg University Hospital, Heidelberg, Germany | |
[5]DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, University of Heidelberg, Heidelberg, Germany | |
[6]Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany | |
[7]Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany | |
[8]Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany | |
[9]Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany | |
[10]Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany | |
[11]Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany | |
[12]National Center for Tumor Diseases (NCT), Heidelberg, Germany | |
[13]Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany | |
[14]Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany | |
[15]German Cancer Consortium (DKTK), Partner Site, Heidelberg, Germany | |
[16]Department of Radiation Oncology, Kantonsspital Winterthur, Brauerstrasse 15, 8400, Winterthur, Switzerland | |
关键词: Fibroblasts; Fibroblast activation protein; FAP; Positron emission tomography; PET; PET-CT; | |
DOI : 10.1186/s13550-021-00761-2 | |
来源: Springer | |
![]() |
【 摘 要 】
PurposeSmall molecules targeting fibroblast activation protein (FAP) have emerged as a new group of tracers for positron emission tomography (PET) in 2018. While most of the existing literature has been focussed on the application of FAP-specific PET in various kinds of cancers, some researchers have, both intentionally or unintentionally, used FAP-specific PET in patients with non-cancerous diseases. The purpose of this systematic review is therefore to summarize the available evidence of FAP-specific PET for non-malignant indications.MethodsThe MEDLINE database was searched for studies presenting the clinical use of FAP-specific PET, the records were screened according to PRISMA guidelines and articles containing patients suffering from non-malignant diseases were included.ResultsSixteen studies with 303 patients were included. FAP-specific PET has been used in cardiac imaging, IgG4-related disease, benign tumors as well as various kinds of inflammation. Two prospective studies on FAP-specific PET for IgG4-related disease show its potential to differentiate inflammatory from fibrotic lesions, which could be used to determine the management of these patients.ConclusionWhile publications on FAP-specific PET for non-malignant indications are mostly limited to case reports and incidental findings, the first retrospective and prospective studies present promising results for IgG4-related as well as cardiovascular disease that warrant further research. Several currently recruiting trials will add to the body evidence in the next few years.【 授权许可】
CC BY
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202106297585694ZK.pdf | 936KB | ![]() |